220 related articles for article (PubMed ID: 25265976)
1. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Badar AA; Perez-Moreno AC; Jhund PS; Wong CM; Hawkins NM; Cleland JG; van Veldhuisen DJ; Wikstrand J; Kjekshus J; Wedel H; Watkins S; Gardner RS; Petrie MC; McMurray JJ
Eur Heart J; 2014 Dec; 35(48):3426-33. PubMed ID: 25265976
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure).
Perez AC; Jhund PS; Stott DJ; Gullestad L; Cleland JG; van Veldhuisen DJ; Wikstrand J; Kjekshus J; McMurray JJ
JACC Heart Fail; 2014 Feb; 2(1):35-40. PubMed ID: 24622117
[TBL] [Abstract][Full Text] [Related]
3. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Perez-Moreno AC; Jhund PS; Macdonald MR; Petrie MC; Cleland JG; Böhm M; van Veldhuisen DJ; Gullestad L; Wikstrand J; Kjekshus J; Lewsey JD; McMurray JJ
JACC Heart Fail; 2014 Apr; 2(2):187-97. PubMed ID: 24720928
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
7. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
8. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Askevold ET; Nymo S; Ueland T; Gravning J; Wergeland R; Kjekshus J; Yndestad A; Cleland JG; McMurray JJ; Aukrust P; Gullestad L
Circ Heart Fail; 2013 Jan; 6(1):91-8. PubMed ID: 23230311
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
[TBL] [Abstract][Full Text] [Related]
10. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).
Mentz RJ; Broderick S; Shaw LK; Fiuzat M; O'Connor CM
J Am Coll Cardiol; 2014 Jan; 63(3):251-8. PubMed ID: 24161322
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
[TBL] [Abstract][Full Text] [Related]
12. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
[TBL] [Abstract][Full Text] [Related]
13. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
[TBL] [Abstract][Full Text] [Related]
14. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
Kjekshus J; Dunselman P; Blideskog M; Eskilson C; Hjalmarson A; McMurray JV; Waagstein F; Wedel H; Wessman P; Wikstrand J;
Eur J Heart Fail; 2005 Oct; 7(6):1059-69. PubMed ID: 16227145
[TBL] [Abstract][Full Text] [Related]
15. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
[TBL] [Abstract][Full Text] [Related]
16. CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.
Ueland T; Nymo SH; Latini R; McMurray JJ; Kjekshus J; Yndestad A; Fucili A; Grosu A; Masson S; Maggioni AP; Gullestad L; Aukrust P; ;
Eur J Heart Fail; 2013 Jul; 15(7):747-55. PubMed ID: 23487539
[TBL] [Abstract][Full Text] [Related]
17. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.
Gravning J; Askevold ET; Nymo SH; Ueland T; Wikstrand J; McMurray JJ; Aukrust P; Gullestad L; Kjekshus J;
Circ Heart Fail; 2014 Jan; 7(1):96-103. PubMed ID: 24284025
[TBL] [Abstract][Full Text] [Related]
20. Lethal outcomes in patients with symptomatic heart failure developed after Q-wave myocardial infarction.
Zaliūnas R; Babarskiene MR; Kavoliūniene A; Slapikiene B; Luksiene D; Slapikas R; Vencloviene J
Medicina (Kaunas); 2004; 40(2):141-8. PubMed ID: 15007273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
